The latest biotech news

News and Trends 10 Jan 2017

Stem Cells in your Teeth can be Stimulated to Naturally Repair Cavities

Researchers from the UK have described a new treatment for cavities that could get rid of fillings and cements by employing an Alzheimer’s drug. Most of us have visited the dentist to fill a cavity. The usual procedure involves removing the damaged area and replacing it with mineral materials. But what if you could let […]

January 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jan 2017

Qiagen acquires Multi Omics Company to boost its Bioinformatics services

Qiagen is entering the promising field of multi-omics data analysis with the acquisition of a bioinformatics company from the US. Qiagen, an upstart looking to break into the field of next-generation sequencing (NGS), has just announced the acquisition of US-based OmicSoft for an undisclosed amount. This transaction will upgrade Qiagen’s bioinformatics services, which will now include multi-omics data analysis and software […]

January 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Jan 2017

Top European VC and CRO fund Young Metabolic Disease Biotech

Eternygen has received €8M in a Series A round led by Epidarex Capital that will be used to advance its pipeline in collaboration with Evotec. Eternygen is a young biotech in Berlin focusing on the treatment of metabolic diseases. The company has now raised €8M in Series A, led by Scottish biotech VC Epidarex Capital. Among the […]

January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 09 at 12.40.51 PM e1483962109441

News and Trends 9 Jan 2017

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that could reach over €1B in milestones. Immatics, an immuno-oncology biotech in Tübingen, Germany, has signed an agreement with biotech giant Amgen. Immatics will receive €28.5M ($30M) upfront and up to €475M ($500M) per program and Amgen will be responsible for clinical development, manufacturing and […]

January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jan 2017

Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors

Servier has signed a deal that could give it access to up to eight bispecific drug candidates with immuno-oncology applications from Pieris Pharmaceuticals. Servier, one of France’s biggest pharma companies, is offering up to €1.7B to US-based Pieris Pharmaceuticals. The team will initially develop five programs that can be later expanded to up to eight. For […]

January 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

crispr platform protocol desktop genetics

News and Trends 6 Jan 2017

‘Packaged’ CRISPR Systems to Standardize novel Biomedical Research

There’s a growing appetite to refine and standardize CRISPR protocols, as its application expands into different areas of genomic research. The Wellcome Trust and Desktop Genomics have recent advances to make it more efficient and controllable. Outside of the high-stakes world of therapeutic CRISPR, which has enjoyed gambling-like investment and whose legal future is unfolding in court, this […]

January 6, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 5 Jan 2017

Shire sells its RNA platform to a US-based Biotech

Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from the platform. The Irish drug giant Shire is giving its MRT program, which includes two mRNA platforms and 12 employees, to US-based RaNA Therapeutics. In exchange, Shire will receive an undisclosed share of equity in the biotech as well […]

January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jan 2017

Cold Sore Cure Company enters the Antibiotic Resistance fight

AiCuris is developing a new antibiotic that might bring hope for patients in which all options to fight infections have been exhausted. AiCuris, a German company leading the fight against infectious diseases, is now entering clinical trials with a new antibiotic. The candidate, AIC499, is a β-lactam effective against a broad range of Gram-negative multi-drug resistant […]

January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jan 2017

This British Biotech is buying its way into the Crowded NASH Space

Tiziana Life Sciences is acquiring candidates to gain leverage in the profitable NASH market, where there’s currently a fierce competition. Tiziana Life Sciences, a biopharmaceutical company from London, is planning to enter the competitive space of non-alcoholic steatohepatitis (NASH). To gain leverage over bigger companies fighting to enter a market expected to hit a massive €38B ($40B) by […]

January 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2017

Bacteria can Protect each other: a New Challenge in Antibiotic Resistance

Researchers have discovered a new mechanism by which antibiotic-resistant bacteria can protect non-resistant pathogens. What are the implications? Scientists have described a new strategy that pathogens use to survive our efforts to eliminate them: resistant bacteria can inactivate antibiotics and allow their neighbor pathogens to grow once the active compound has reached low enough levels. The […]

January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2017

New German Immuno-oncology Partnership takes on Solid Tumors

TCR2 Therapeutics is initiating a partnership with academia to boost its TCR technology with the aim of overcoming the huge challenges of treating solid tumors. TCR2 Therapeutics, a Boston immuno-oncology startup launched in 2015 and funded by the Munich biotech mafia, is starting the year with a multi-year collaboration with the University Hospital of Ludwig-Maximilians-University (LMU) in, […]

January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Jan 2017

An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics

The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalized medicine. The EU Horizon 2020 has kicked off the year with a project to develop, validate, and exploit methods for the personalized treatment of multiple sclerosis (MS). The 21 institutions from 12 European countries and […]

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us